×
ADVERTISEMENT

DECEMBER 19, 2024

FDA Approves Ensacove for ALK-Positive Locally Advanced or Metastatic NSCLC


Originally published by our sister publication Clinical Oncology News

By Clinical Oncology News Staff

The FDA approved ensartinib (Ensacove, Xcovery Holdings) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.

Efficacy was evaluated in eXalt3 (ClinicalTrials.gov. Identifier: NCT02767804), an open-label, randomized, active-controlled, multicenter trial in 290 patients